Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.94 |
| ▸ | FLT1 | P17948 | 1/20 | 0.94 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.94 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.94 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.94 |
| ▸ | FLT4 | P35916 | 1/20 | 0.94 |
| ▸ | KDR | P35968 | 1/20 | 0.94 |
| ▸ | FRS2 | Q8WU20 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16342978 | 0.97 | FGFR1 (1.00) | FGFR1FLT1FGFR2FGFR4FGFR3 | |
| Hydrochloric Acid SCHEMBL23928844 | 0.96 | FGFR1 (0.98) | FGFR1FLT1FGFR2FGFR4FGFR3 | |
| Hydrochloric Acid SCHEMBL30921860 | 0.96 | FGFR1 (0.98) | FGFR1FLT1FGFR2FGFR4FGFR3 | |
| SCHEMBL16342642 | 0.89 | FGFR1 (0.81) | FGFR1FLT1FGFR2FGFR4FGFR3 | |
| SCHEMBL14863974 | 0.89 | FGFR1 (0.82) | FGFR1FLT1FGFR2FGFR4FGFR3 | |
| SCHEMBL16342739 | 0.89 | FGFR1 (0.84) | FGFR1FLT1FGFR2FGFR4FGFR3 | |
| SCHEMBL16342562 | 0.88 | FGFR1 (0.84) | FGFR1FLT1FGFR2FGFR4FGFR3 | |
| SCHEMBL17745066 | 0.88 | FGFR1 (0.83) | FGFR1FLT1FGFR2FGFR4FGFR3 | |
| SCHEMBL16342594 | 0.88 | FGFR1 (0.83) | FGFR1FLT1FGFR2FGFR4FGFR3 | |
| SCHEMBL14863028 | 0.88 | FGFR1 (1.00) | FGFR1FLT1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391082-B2 | Protein kinase inhibitors | ORION CORPORATION (FI) | 2019-08-27 | — | — | US | claimed |
| US-20180250272-A1 | PROTEIN KINASE INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-09-06 | — | — | US | claimed |
| US-10391082-B2 | Protein kinase inhibitors | ORION CORPORATION (FI) | 2019-08-27 | — | — | US | disclosed |
| US-20180250272-A1 | PROTEIN KINASE INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-09-06 | — | — | US | disclosed |
| US-20160346254-A1 | PROTEIN KINASE INHIBITORS | ORION CORP (FI) | 2016-12-01 | — | — | US | disclosed |
| US-9447091-B2 | Protein kinase inhibitors | ORION CORPORATION (FI) | 2016-09-20 | — | — | US | disclosed |
| EP-2766354-B1 | PROTEIN KINASE INHIBITORS | ORION CORP (FI) | 2016-05-18 | — | — | EP | disclosed |
| US-20150011548-A1 | PROTEIN KINASE INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011548-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | FGFR1 1/4885FLT1 322/4885FGFR2 4/4885 |
| US-20160346254-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | FGFR1 1/4885FLT1 322/4885FGFR2 4/4885 |
| US-20180250272-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | FGFR1 1/4885FLT1 306/4885FGFR2 4/4885 |
| US-10391082-B2 | Protein kinase inhibitors | FGFR1, FGFR3, FGFR4 | FGFR1 1/4885FLT1 306/4885FGFR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.